Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

E Gobbini, R Chiari, P Pizzutillo, P Bordi, L Ghilardi, S Pilotto, G Osman, F Cappuzzo, F Cecere, F Riccardi, V Scotti, O Martelli, G Borra, E Maiello, A Rossi, P Graziano, V Gregorc, C Casartelli, C Sergi, A Del ConteA Delmonte, C Bareggi, D Cortinovis, P Rizzo, F Tabbò, G Rossi, E Bria, D Galetta, M Tiseo, M Di Maio, S Novello

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. PATIENTS: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. RESULTS: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9-11.2] and 11.1 months [CI 95% 9.2-13.8], respectively, while TTF were 10.2 [CI 95% 8.5-12.6] and 11.9 months [CI 95% 9.7-17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3-33.7] in PFS and 30.4 months [CI 95% 24.7-34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8-54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0-73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6-NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3-34.0)] (P 
Original languageEnglish
Pages (from-to)10.1007/s12094-019-02222-8
Number of pages8
JournalClinical and Translational Oncology
DOIs
Publication statusPublished - Oct 19 2019

Keywords

  • ALK inhibitors
  • Lung cancer
  • Sequence

Fingerprint

Dive into the research topics of 'Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study'. Together they form a unique fingerprint.

Cite this